MIRA Pharmaceuticals, Inc. Common Stock Total Liabilities
MIRA Pharmaceuticals, Inc. Common Stock total liabilities. Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has total liabilities worth $40.82K USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of MIRA Pharmaceuticals, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Total Liabilities of MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
Total liabilities of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Graphene Ltd
AU:FGR
|
Australia | AU$1.01 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
Korea | ₩29.68 Billion |
|
First Au Ltd
AU:FAU
|
Australia | AU$333.42K |
|
Maat Pharma SA
PA:MAAT
|
France | €40.58 Million |
|
Petratherm Ltd
AU:PTR
|
Australia | AU$466.42K |
|
Jasa Kita Bhd
KLSE:8648
|
Malaysia | RM1.61 Million |
|
Bonava AB (publ)
ST:BONAV-A
|
Sweden | Skr9.17 Billion |
|
Rifa Ind
KO:000760
|
Korea | ₩64.66 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down MIRA Pharmaceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MIRA Pharmaceuticals, Inc. Common Stock total assets.
Liquidity & Leverage Metrics
MIRA Pharmaceuticals, Inc. Common Stock Total Liabilities Ratios Explained
MIRA Pharmaceuticals, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 200.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MIRA Pharmaceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $702.07K | -2.94% |
| 2024-12-31 | $723.35K | +29.61% |
| 2023-12-31 | $558.10K | -61.62% |
| 2022-12-31 | $1.45 Million | +32.96% |
| 2021-12-31 | $1.09 Million | +1110.44% |
| 2020-12-31 | $90.36K | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical mar… Read more